Drugs / Decartes-08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06799247 | May 2025 → Nov 2026 expected | generalized myasthenia gravis | Cartesian Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | Cartesian Therapeutics | Regulatory Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis cartesiantherapeutics.com ↗
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | Cartesian Therapeutics | Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis cartesiantherapeutics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decartes-08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799247 ↗ |